Calliditas Total Current Liabilities vs Common Stock Total Equity Analysis
CALT Stock | USD 38.90 0.13 0.34% |
Calliditas Therapeutics financial indicator trend analysis is way more than just evaluating Calliditas Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Calliditas Therapeutics is a good investment. Please check the relationship between Calliditas Therapeutics Total Current Liabilities and its Common Stock Total Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calliditas Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.
Total Current Liabilities vs Common Stock Total Equity
Total Current Liabilities vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Calliditas Therapeutics Total Current Liabilities account and Common Stock Total Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Calliditas Therapeutics' Total Current Liabilities and Common Stock Total Equity is 0.67. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Calliditas Therapeutics, assuming nothing else is changed. The correlation between historical values of Calliditas Therapeutics' Total Current Liabilities and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Calliditas Therapeutics are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Total Current Liabilities i.e., Calliditas Therapeutics' Total Current Liabilities and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | 0.67 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Current Liabilities
Total Current Liabilities is an item on Calliditas Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Calliditas Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from Calliditas Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Calliditas Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calliditas Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.At this time, Calliditas Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 19.7 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (40.25) in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 7.1M | 12.5M | 73.2M | 76.9M | Depreciation And Amortization | 1K | 12.9M | 16.6M | 17.4M |
Calliditas Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Calliditas Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Calliditas Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 845.2M | 1.5B | 1.5B | 2.0B | 1.9B | 1.0B | |
Other Current Liab | 25.6M | 51.8M | 13.9M | 18.0M | 287.9M | 302.3M | |
Total Current Liabilities | 53.4M | 105.6M | 135.4M | 325.2M | 407.1M | 427.5M | |
Total Stockholder Equity | 788.1M | 1.2B | 1.0B | 766.3M | 334.8M | 582.2M | |
Property Plant And Equipment Net | 6.1M | 5.4M | 39.6M | 31.9M | 54.2M | 57.0M | |
Net Debt | (747.5M) | (991.5M) | (742.3M) | (520.3M) | 5.4M | 5.7M | |
Retained Earnings | (488.1M) | (918.6M) | (1.5B) | (1.8B) | (2.3B) | (2.2B) | |
Accounts Payable | 24.4M | 53.8M | 68.0M | 160.4M | 100.6M | 55.2M | |
Cash | 753.5M | 996.3M | 955.5M | 1.2B | 973.7M | 694.4M | |
Non Current Assets Total | 24.1M | 469.6M | 447.1M | 540.8M | 625.4M | 656.7M | |
Cash And Short Term Investments | 753.5M | 996.3M | 955.5M | 1.2B | 973.7M | 694.4M | |
Common Stock Total Equity | 667K | 1.4M | 1.5M | 2.0M | 2.3M | 1.2M | |
Common Stock Shares Outstanding | 36.9M | 44.9M | 50.8M | 53.0M | 53.7M | 42.4M | |
Liabilities And Stockholders Equity | 845.2M | 1.5B | 1.5B | 2.0B | 1.9B | 1.0B | |
Other Current Assets | 1.6M | 2.3M | 22.8M | 1K | 92.8M | 97.4M | |
Other Stockholder Equity | 1.3B | 2.1B | 2.5B | 2.6B | 2.6B | 1.6B | |
Total Liab | 57.1M | 250.2M | 451.6M | 1.2B | 1.6B | 1.6B | |
Property Plant And Equipment Gross | 6.1M | 5.4M | 39.6M | 35.6M | 62.3M | 65.5M | |
Total Current Assets | 821.1M | 1.0B | 1.0B | 1.4B | 1.3B | 772.7M | |
Accumulated Other Comprehensive Income | (45K) | (6.1M) | (27.0M) | 9.3M | (5.2M) | (5.0M) | |
Common Stock | 1.5M | 2.0M | 2.1M | 2.4M | 2.7M | 1.6M | |
Property Plant Equipment | 6.1M | 5.4M | 39.6M | 31.9M | 36.7M | 38.5M | |
Net Tangible Assets | 772.0M | 749.1M | 608.9M | 282.4M | 324.8M | 479.2M | |
Other Assets | 1.9M | 600K | 8.1M | (1K) | 1.0 | 0.95 | |
Non Current Liabilities Total | 3.8M | 144.5M | 316.2M | 861.5M | 1.2B | 1.2B | |
Net Invested Capital | 788.1M | 1.2B | 1.2B | 1.5B | 1.3B | 1.0B | |
Net Working Capital | 767.8M | 931.2M | 877.3M | 1.1B | 868.0M | 814.3M | |
Capital Stock | 1.5M | 2.0M | 2.1M | 2.4M | 2.7M | 2.2M |
Pair Trading with Calliditas Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calliditas Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calliditas Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Calliditas Stock
0.65 | BKRKF | PT Bank Rakyat | PairCorr |
0.64 | PPERF | Bank Mandiri Persero | PairCorr |
0.59 | PPERY | Bank Mandiri Persero | PairCorr |
0.54 | BKRKY | Bank Rakyat | PairCorr |
0.54 | PBCRY | Bank Central Asia | PairCorr |
The ability to find closely correlated positions to Calliditas Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calliditas Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calliditas Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calliditas Therapeutics to buy it.
The correlation of Calliditas Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calliditas Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calliditas Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Calliditas Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Calliditas Stock Analysis
When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.